Ola Skanung new CFO at Cyxone, replacing Henrik Hang

Cyxone (publ), a biotech company in autoimmune diseases, announces today that CFO Henrik Hang leaves the company at his own request. Ola Skanung, previously the CFO at Cyxone, succeeds Henrik.

Henrik joined the company as CFO in August 2021 and has during his time in Cyxone contributed to, among other things, fundraising and restructuring to enable the planned development activities to be performed according to current regulations.

Ola Skanung will take over the role as CFO from Henrik as of November 2022.

“Henrik Hang has been a great asset to the company since he joined Cyxone. Henrik has performed several valuable changes in the company’s internal workflow and structures. We are very grateful for his contributions and wish Henrik the best of luck in his future engagements. We are at the same time pleased to welcome Ola Skanung to Cyxone. Ola knows the company well from previous years and brings a lot of knowledge and experience in his role,” comments Carl-Magnus Högerkorp, acting CEO, Cyxone.

Contact

Carl-Magnus Högerkorp, acting CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CEST on 31 August 2022.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

Tags: